Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Feb
14
Today In Oncology
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
Oncolytic Virus Triggers Immune System Against Glioblastoma Cells
Adjuvant Durvalumab in Resected Early-Stage NSCLC
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
Young-Onset Pancreatic Cancer Can Alcohol Consumption Raise Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo